AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 152 min read$VSTM

Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC

Verastem's KRAS inhibitor, VS-7375, showed a 75% ORR in lung cancer trials. The company plans FDA meetings and further trials. Competitors like MSD, Lilly, and Roche are also developing KRAS-targeting drugs. More data is expected by year-end 2026.

Original reporting
finance.yahoo.com
Published Oct 15, 2026, 4:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 4:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$VSTMBullishHigh
01

Why it matters

The disclosed ORR and safety profile are the first public read‑out of these trials, representing a material catalyst for the stock.

02

Market read

New clinical data for a biotech can move the stock significantly; traders should watch pre‑market activity and upcoming FDA meeting requests.

03

What to watch

Regulatory timeline uncertainties and competition from MSD, Lilly, and Roche could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Verastem is advancing its pan‑RAS inhibitor VS‑7375 in multiple tumor types, with data now emerging from the TARGET‑D 101 and 202 studies.

Company-level read

Ticker impact

$VSTMBullishHigh confidence
Context

Verastem reported new Phase II data showing a 75% ORR for its KRAS inhibitor in first‑line NSCLC and ongoing safety data across dose levels.

Expected impact

upward pressure as investors price in the favorable ORR and upcoming FDA discussions.

Evidence & confidence

Phase II data with high response rates are material for a biotech and often trigger price appreciation ahead of further trial milestones.

Market effects

Sector

Strengthens the KRAS‑targeted oncology segment and may boost peer valuations.

Regional

Primarily U.S. biotech market, with limited immediate regional effect.

Global

Adds to global interest in KRAS inhibitors, potentially influencing international biotech investors.

Counterpoint

What could challenge this read

If later trials fail to confirm durability, the initial hype could reverse sharply.

Key entities

  • Company
    Verastem Oncology

    Developer of KRAS inhibitor VS‑7375, listed on NASDAQ under VSTM.

Read at source← All news

Related articles

OCT 15
$VSTMHighAI 8/10

Mizuho raises Verastem stock price target on strong trial data

Mizuho raised its price target on Verastem Inc. (VSTM) to $14 from $13, citing strong clinical trial data for its oral KRAS G12D inhibitor. The stock trades at $7.71, with analysts' targets ranging from $12 to $24. Verastem plans a Phase 3 study and completed a $250 million financing. Multiple analysts maintain positive ratings, with price targets up to $19.

investing.com2 min
OCT 14
$VSTMHighAI 9/10

Verastem, Inc. entered into an underwriting agreement with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named…

Verastem, Inc. (VSTM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 14, 2026, Verastem, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named in Schedule I thereto (the “Un

SEC EDGAR 8-K2 min
OCT 14
$VSTMMedAI 9/10

Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III

Verastem (VSTM) reported positive results for its KRAS G12D drug in pancreatic, colorectal, and lung cancer trials. Key data includes a 43% response rate in lung cancer and 75% in frontline lung cancer combinations. The FDA agreed to the Phase III pancreatic cancer study design. The company expects to complete Phase II enrollments by year-end and has secured financing to fund operations into 2028.

finance.yahoo.com2 min